Pathos AI raises $237M at $3B valuation with Bristol Myers partnership

· Health · United States

Pathos AI, a New York-based AI-driven biotech, raised a $237 million Series E at a $3 billion valuation, the company said. The round came in below the $300 million the company had sought. The deal brings together a large dataset from Tempus, AI analysis from Pathos and drug development from Bristol Myers Squibb, under a neuro partnership the companies also signed. The raise is one of the larger recent financings for an AI-native drug developer, a category that has attracted growing investor interest as pharma companies look to computational methods to find new medicines.

Why it matters：Large AI-drug financings tied to pharma partners show how computational drug discovery is being funded and integrated into big pharma pipelines.

Key points

  • New York-based Pathos raised a $237 million Series E.
  • The round valued the company at $3 billion, below its $300 million target.
  • The deal pairs Tempus data and Pathos AI with Bristol Myers drug development.

Sources (original reporting)

More stories from this day